Organogenesis Holdings Inc. praises CMS for payment reform for skin substitutes and cellular and tissue-based products under the CY 2026 Physician Fee Schedule. CEO Gary S. Gillheeney, Sr. commends CMS for finalizing FDA classifications and a per centimeter square payment methodology, which will increase access to PMA products and address abuse in the current system. Organogenesis remains committed to expanding access to life-saving technologies and incentivizing innovation in the regenerative medicine space. With over forty years of experience, Organogenesis believes they are well-positioned in the skin substitutes market for 2026 and beyond.

Read more at GlobeNewswire: Organogenesis Applauds CMS’s Significant Step In Payment